RxDoctor Payments DataLook up a doctor →

Elie Fahed, MD

Hematology & Oncology · Casper, WYNPI 1356492482

Payments from drug & device makers

$391,300in general payments, 2019–2025

Across 1,275 payments — averaging $306.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$156K
  • Daiichi Sankyo Inc.$45K
  • Astellas Pharma US Inc$29K
  • Bristol Myers Squibb$23K
  • AstraZeneca$21K
  • Incyte Corporation$18K
  • plus $98K from 54 others

What the payments were for

  • Consulting fees$153,53539%
  • Speaking & faculty fees$163,32342%
  • Travel & lodging$46,26912%
  • Food & beverage$26,2357%
  • Education$1,9380%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
E.r. Squibb & Sons, L.L.C.207$156,112
Daiichi Sankyo Inc.66$44,740
Astellas Pharma US Inc42$28,860
Bristol Myers Squibb53$22,630
AstraZeneca(2 entities)76$21,063
Incyte Corporation62$18,314
GSK29$16,626
Seagen Inc.39$11,049
ADC Therapeutics America, Inc.10$9,122
Bayer23$6,259
Pfizer73$5,751
Stemline Therapeutics Inc.7$5,085
Beigene USA, Inc.15$4,191
Karyopharm Therapeutics Inc.11$4,080
Avyxa Pharma, LLC8$3,805
Sanofi34$3,791
Janssen Scientific Affairs, LLC9$3,495
Astellas Pharma Global Development4$2,785
Boehringer Ingelheim8$1,692
Varian Medical Systems, Inc.3$1,575
Johnson & Johnson(2 entities)39$1,523
G1 Therapeutics, Inc.2$1,522
Siemens Medical Solutions USA, Inc.1$1,400
Takeda Pharmaceuticals U.S.A., Inc.6$1,202
US Oncology Corporate, Inc.2$1,163
Novartis58$981
Blueprint Medicines Corporation4$963
Genentech USA, Inc.44$865
Amgen(2 entities)35$853
Macrogenics, Inc.1$800
Merck42$729
Exelixis Inc.5$695
Myriad Genetic Laboratories, Inc.6$518
AbbVie26$498
Gilead(2 entities)16$473
Beigene, Ltd.1$450
EMD Serono, Inc.16$431
Pharmacyclics LLC, An Abbvie Company12$378
Sumitomo Pharma America, Inc.14$353
Regeneron Healthcare Solutions, Inc.4$284
Sanofi-aventis U.S. LLC3$236
Myovant Sciences Inc.9$230
AVEO Pharmaceuticals, Inc.13$221
Novocure GmbH1$200
Eisai Inc.9$167
Lilly USA, LLC10$161
Jazz Pharmaceuticals Inc.3$155
Medtronic2$152
Athenex Pharmaceutical Division, LLC1$150
Coherus Oncology, Inc.3$147
Pharmaessentia USA Corporation1$125
Tempus AI, Inc3$123
Sobi, Inc6$116
Heron Therapeutics, Inc.5$108
Ipsen Biopharmaceuticals, Inc5$101
Cardinal Health 110 LLC1$100
Comsort, Inc1$100
Adaptive Biotechnologies Corporation2$88
Dova Pharmaceuticals5$87
Array Biopharma Inc5$81

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few hematology & oncology providers in Wyomingto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$7,533,242
Medicare patients
646
Services billed
245,943

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lenalidomide51$818,203
RevlimidLenalidomide23$420,509
CabometyxCabozantinib S-Malate13$330,322
VerzenioAbemaciclib20$300,574
EliquisApixaban43$45,543
Abiraterone Acetate20$12,531
Exemestane19$2,051
Anastrozole51$1,559
Tamoxifen Citrate44$1,281
Potassium Chloride68$943
Letrozole37$840
Ondansetron OdtOndansetron39$558
Prochlorperazine Maleate43$383
Acyclovir41$357
Dexamethasone16$308

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$22,630$420,50923 claims
Exelixis Inc.Cabometyx$695$330,32213 claims
Lilly USA, LLCVerzenio$161$300,57420 claims
PfizerEliquis$5,751$45,54343 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$3,495$12,53120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few hematology & oncology providers in Wyomingon file to place this against a meaningful peer group, so we don't.

Other hematology & oncology in Casper

See the full list for Wyoming

Where these figures come from

Is this you, or does something look wrong? →